CareRx Initiates Quarterly Dividend
Toronto, Ontario--(Newsfile Corp. - September 15, 2025) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced its intention to pay a quarterly dividend on its outstanding common shares ("Common Shares"). "The initiation of a quarterly dividend reflects the CareRx team's dedication to delivering robust cash generation and a disciplined
2025-09-15 7:30 AM EDT | CareRx Corporation
Healthcare Special Opportunities Fund Announces September 2025 Quarterly Distribution
Toronto, Ontario--(Newsfile Corp. - September 12, 2025) - LDIC Inc. (the "Manager"), the manager of Healthcare Special Opportunities Fund (TSX: MDS.UN) (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.06010 per Class A unit and US$0.05460 per Class U unit. The distribution will be paid on or before October 10, 2025, to unitholders of record on September 30, 2025. For further informatio
Banking / Financial Services, Healthcare and Hospitals
2025-09-12 10:38 AM EDT | Healthcare Special Opportunities Fund
NewOrg's Data Management Platform Helps Making Headway Foundation Enhance Support for Pediatric Brain Tumor Families
Washington, D.C.--(Newsfile Corp. - September 11, 2025) - NewOrg Management System, Inc., a leading provider of customizable, cloud-based data management solutions for nonprofits and local governments, announced today that the Making Headway Foundation has implemented NewOrg's platform to streamline service delivery, improve documentation, and enhance coordination for families affected by pediatric brain and spinal cord tumors. Since 1996, the Making Headway Foundation has suppor
Computer Software, Healthcare and Hospitals, Housing, Aboriginal / Indigenous
2025-09-11 1:00 PM EDT | NewOrg Management System Inc
FONAR Announces Financial Results for Fiscal 2025
Cash and Cash Equivalents was $56.3 million at June 30, 2025 and the previous fiscal year. Total Revenues - Net increased 1% to $104.4 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Income from Operations decreased 30% to $11.6 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Net Income decreased 24% to $10.7 million for the fiscal year ended
Technology, Healthcare and Hospitals
2025-09-11 8:27 AM EDT | Fonar Corporation
medmix Announces Strategic Partnership with Gurit for Sustainable Solutions for Industrial Bonding Applications
Baar, Switzerland--(Newsfile Corp. - September 11, 2025) - medmix AG Neuhofstrasse 20 CH-6430 Baar communications@medmix.com www.medmix.swiss MEDIA RELEASE
Technology, Construction / Building, Healthcare and Hospitals, Household / Consumer / Cosmetics
2025-09-11 3:51 AM EDT | medmix AG
Envoy Medical Issues Letter to Shareholders and Provides Update on Recent Accomplishments
White Bear Lake, Minnesota--(Newsfile Corp. - September 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today issued a letter to shareholders commenting on recent accomplishments and other operational updates from Chief Executive Officer, Brent Lucas. Dear Shareholders: The third quarter of 2025 has been one of tremendous progress and momentum for Envoy Medical. As "Amer
Biotechnology, Healthcare and Hospitals
2025-09-10 8:00 AM EDT | Envoy Medical, Inc.
Adia Nutrition Expands Rapidly, Tripling Sales Force with Regional Teams to Fuel U.S. and Worldwide Growth
Winter Park, Florida--(Newsfile Corp. - September 9, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine, is excited to announce a rapid expansion of its sales operations by tripling its sales force and creating four specialized teams to accelerate growth and market reach for its innovative Adialabs products. This strategic restructuring divides sales operations into dedicated teams for the East Coast, West Coast, Central U.S., and a team focused on nationa
Healthcare and Hospitals, Health
2025-09-09 8:30 AM EDT | Adia Nutrition Inc.
Envoy Medical Secures Four New Global Patents, Expanding Its Leadership Position in Fully Implantable Hearing Technology
White Bear Lake, Minnesota--(Newsfile Corp. - September 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of four new global patents. These patents expand the company's global intellectual property portfolio and mark another strategic step in delivering next-generation cochlear implant solutions that offer patients discreet, 24/7 hearing experience wit
Biotechnology, Healthcare and Hospitals
2025-09-09 8:00 AM EDT | Envoy Medical, Inc.
Envoy Medical to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025
White Bear Lake, Minnesota--(Newsfile Corp. - September 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025 in New York City. Mr. Lucas' presentation is now av
Biotechnology, Healthcare and Hospitals
2025-09-08 8:00 AM EDT | Envoy Medical, Inc.
Adia Nutrition Inc. Identifies Over 20 Million Potentially Improperly Issued Shares and Initiates Process to Return Shares to Treasury
Winter Park, Florida--(Newsfile Corp. - September 4, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company focused on advancing stem cell therapies for orthopedics, pain management, wound repair, and regenerative medicine, today announced that it has identified over 20 million shares that may have been improperly issued as part of an ongoing review of its historical share structure. This discovery comes from a comprehensive internal audit designed to strengthen the integr
Healthcare and Hospitals, Health
2025-09-04 8:45 AM EDT | Adia Nutrition Inc.
Discovery Senior Living Showcases Bespoke Lifestyle at the Watermark at Brooklyn Heights with Pet-Centered Living
Bonita Springs, Florida--(Newsfile Corp. - September 3, 2025) - Discovery Senior Living ("Discovery" or the "Company"), one of the largest and most trusted operators of senior housing in the U.S., is pleased to highlight one of its unique pet-centered lifestyle initiatives at The Watermark at Brooklyn Heights, underscoring the Company's ability to create highly bespoke living environments tailored to local markets.
Healthcare and Hospitals, Real Estate, Housing
2025-09-03 4:38 PM EDT | Discovery Senior Living
Envoy Medical Successfully Reaches Three-Month Follow-Up Milestone in Clinical Trial of the Acclaim Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - September 3, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today announced that the patients in the first stage of its pivotal clinical trial for the investigational Acclaim® fully implanted cochlear implant have successfully reached their three-month follow-up milestone. During this timeframe, no serious adverse events (SAEs) or unan
Biotechnology, Healthcare and Hospitals
2025-09-03 8:00 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-03 7:45 AM EDT | Phio Pharmaceuticals Corp.
Scryb Reports Financial Results for Q3 2025: Positive Outlook for Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - September 3, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company") has filed financial results for its third quarter ended June 30, 2025 ("Q3 2025"), and also provides commentary on Scryb's largest holding, Cybeats, which filed its second quarter ended June 30, 2025 Interim Financial Statements and Management's Discussion and Analysis ("MD&A"). Scryb's reported results for Q3 2025 reflect the transition to equity accounting for C
Biotechnology, Healthcare and Hospitals, Health
2025-09-03 7:20 AM EDT | Scryb Inc.
Kovo+ Announces Corporate Update
Calgary, Alberta--(Newsfile Corp. - September 2, 2025) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") is pleased to announce that, further to its news release dated July 31, 2025, it has entered into a fourth extension agreement (the "Extension Agreement") with Avonlea Ventures #2 Inc. ("AVI"), Kovo's largest shareholder and secured creditor, whereby AVI has agreed, among other things: (i) to extend the terms of the 2nd Amended & Restat
Technology, Healthcare and Hospitals, Internet Technology
2025-09-02 11:15 PM EDT | Kovo+ Holdings Inc.
Adia Med Finalizing In-Network Access with the Nation's Largest Health Insurers Including Medicare, Medicaid, Humana, Cigna, and Florida Blue
Winter Park, Florida--(Newsfile Corp. - September 2, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a rising name in regenerative medicine, is thrilled to announce a transformative step toward expanding patient access to its innovative stem cell therapies. The company is finalizing in-network provider status with some of the nation's largest health insurance providers-Humana, Florida Blue, Cigna, Medicare, and Medicaid-positioning Adia to bring its advanced treatments to millions of patients.
Healthcare and Hospitals, Health
2025-09-02 10:27 AM EDT | Adia Nutrition Inc.
Theralase(R) Extends Warrants
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,840,000 share purchase warrants ("Warrants")
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-08-29 4:30 PM EDT | Theralase Technologies Inc.
LevelJump Announces 2025 Second Quarter Results
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and six months ended June 30, 2025. Financial and Operational Highlights Revenues were $4.7 million in the second quarter compared to $4.4 million in the same period the prior year, an increase of 6.2%. For t
Healthcare and Hospitals, Health
2025-08-29 10:42 AM EDT | LevelJump Healthcare Corp.
Adia Nutrition Joins PI Doctors Elite Community as Preferred Vendor Unlocking Access to a $50 Billion Personal Injury Care Market
Winter Park, Florida--(Newsfile Corp. - August 28, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company focused on regenerative medicine and personalized healthcare, announced that its laboratory division, Adia Labs, has been selected as a preferred vendor for the PI Doctors Elite Community. This national network includes over 4,000 personal injury physicians across various specialties, providing Adia Labs with access to a robust referral base serving injury patients throughou
Healthcare and Hospitals, Health
2025-08-28 9:00 AM EDT | Adia Nutrition Inc.
Cosmo Receives Positive CHMP Opinion for Winlevi(R) for Treatment of Acne in Adults and Adolescents, Following Successful Re-Examination
Dublin, Ireland--(Newsfile Corp. - August 27, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending European approval of Winlevi® (clascoterone 1% cream) for the treatment of facial acne vulgaris in both adults and adolescents aged 12 to <18 years. The
Healthcare and Hospitals, Health
2025-08-27 1:05 AM EDT | Cosmo Pharmaceuticals N.V.